FOXP3 and prostate carcinoma: Similarly, two studies identified a CD8+FoxP3+ subset of TREG in patients with colorectal and prostate cancer, suggesting that FoxP3 can be expressed in CD8+ T cells and promote an immunosuppressive phenotype in cancer patients [125, 126].